Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03452202 · ClinicalTrials.gov registry record · NA

Using tDCS in Speech-based Stroke Rehabilitation

A NA study of Apraxia of Speech, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
2
Study locations

NCT03452202 is a NA study of Apraxia of Speech that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 24 participants, below the 37-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03452202, a NA study of Apraxia of Speech, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.

Conditions Studied

Apraxia of Speech

Interventions

  • DEVICE Soterix 1x1 line tDCS low-intensity stimulator
  • DEVICE Sham

Study Locations (2)

New York

  • New York University School of Medicine - New York
  • Burke Rehabilitation Hospital - White Plains

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2019-01-11
Est. Completion 2026-10-30
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03452202

The ClinicalTrials.gov registry entry for NCT03452202 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 5 other Apraxia of Speech trials with a reported enrollment target (35% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Apraxia of Speech appearing as the primary indexed condition, and to 2 interventions - of which Soterix 1x1 line tDCS low-intensity stimulator is the first listed.

NCT03452202 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03452202 about?

NCT03452202 is a clinical study titled "Using tDCS in Speech-based Stroke Rehabilitation". The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp,...

What is the current status of trial NCT03452202?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2019-01-11. Estimated completion is 2026-10-30.

What conditions does trial NCT03452202 study?

This clinical trial studies the following conditions: Apraxia of Speech.

What interventions are being tested in trial NCT03452202?

The interventions under investigation include: Soterix 1x1 line tDCS low-intensity stimulator (DEVICE), Sham (DEVICE).

Who is sponsoring clinical trial NCT03452202?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03452202 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Apraxia of Speech

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Apraxia of Speech

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.